Successful companies don't all succeed the same way...

Careful of McKonsultancies who say otherwise...

One notable feature of this year’s Pharmaceutical Innovation and Invention Index (full report available for download there…) is how fresh the field is - look at how much change there is from 2024…

And for the Invention Index…

But, as I said in my conversation for STAT, “successful companies don’t all succeed in the same way. Roche, with a high number of regulatory approvals and many mature products, looks very different from Regeneron, a smaller firm with a focus on R&D and no new drug launches last year. And those are very different from UCB, an older firm that IDEA rated as a potential comeback story.”

There is a huge variety of portfolio and investment strategies at play - acquisition vs development, companies who can launch and companies who can’t… A year is a long time in our industry, and despite the top 30 being the top of a very big pyramid of companies in our space, we continue to see the effects of those strategies making a big difference year on year - the kind of consistency that AZ has shown since the years when we ‘definitely’ thought that Pfizer was going to own them has been notable because it is the result of a long, intentional direction - I go back 6 years to my podcast with Mene Pangalos, where it was clear that the intentionality of the simplicity of the 5Rs (now 6Rs…) was a valuable organising principle - the asymmetry of those ‘rights’ has been shown to work in early phase.